Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes
Autor: | Tanja Milicic, Ljiljana Lukic, Nebojsa Lalic, Miroslava Gojnic Dugalic, Jelena Stanarcic Gajovic, Milica Stoiljkovic, Veljko Jeremic, Katarina Lalic, Marija Macesic, Aleksandra Jotic |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Continuous subcutaneous insulin infusion Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism 03 medical and health sciences 0302 clinical medicine Pregnancy Diabetes mellitus Internal Medicine medicine 030212 general & internal medicine Original Research Type 1 diabetes Obstetrics business.industry Insulin Incidence (epidemiology) Glucose variability medicine.disease 3. Good health Metabolic control analysis Observational study business Cohort study |
Zdroj: | Diabetes Therapy |
ISSN: | 1869-6961 1869-6953 |
DOI: | 10.1007/s13300-020-00780-7 |
Popis: | Introduction We evaluated the effectiveness of long-term continuous subcutaneous insulin infusion (CSII) compared with multiple daily insulin (MDI) injections for glycaemic control and variability, hypoglycaemic episodes and maternal/neonatal outcomes in pregnant women with pre-existing type 1 diabetes (pT1D). Methods Our observational cohort study included 128 consecutive pregnant women with pT1D, who were treated from 1 January 2010 to 31 December 2017. Of 128 participants, 48 were on CSII and 80 were on MDI. Glycaemic control was determined by glycated haemoglobin (HbA1c) (captured in preconception and each trimester of pregnancy). Glucose variability (GV) was expressed as the coefficient of variation (CV) [calculated from self-monitoring of blood glucose (SMBG) values], and hypoglycaemia was defined as glucose values < 3.9 mmol/l. The data on maternal and neonatal outcomes were collected from obstetrical records. Results Duration of the treatment was 8.8 ± 5.3 years in the CSII and 12.6 ± 8.0 years in the MDI group. The CSII lowered HbA1c in preconception (7.1 ± 0.1 vs. 7.9 ± 0.2%, p = 0.03) and the first (6.9 ± 0.1 vs. 7.7 ± 0.2%, p = 0.02), second (6.6 ± 0.1 vs. 7.2 ± 0.1%, p = 0.003) and third (6.5 ± 0.1 vs. 6.8 ± 0.1%, p = 0.02) trimesters significantly better than MDI. Significantly lower CV was observed only for fasting glycaemia in the first trimester (17.1 vs 28.4%, p |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |